univers coverag
calendar event
regulatori event fda adcom brief doc anesthet analges drug product
exparel european scientif advisori group meet rubraca
medic meet advanc genom biolog technolog associ
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
bottom line herein preview our/street expect commercial-stag compani
coverag univers admittedli number compani alreadi pre-announc
result last month therebi remov earn beat/miss uncertainti consequ believ
investor focu management commentari regard growth project clinical/regulatori catalyst
expect set tone yr compani continu face uphil battl
commerci busi mp mp discuss new product launch
makena auto-injector ferahem well strategi win market share pulmonari arteri
hypertension/pah primari biliari cholangitis/pbc mp necessari
provid assur investor embark compani issu bullish
guidanc yr op op look forward management expect growth
driver lever help achiev sale goal convers lead disappoint given
high impact catalyst guid re-submiss sparsentan trial protocol
op top-lin data ulcer coliti op announcements/upd may
coincid earn result lastli introduc ultragenyx op
list commerci compani mepsevii mucopolysaccharidosi enter commerci stage
forthcom regulatori decis burosumab x-link hypophosphatemia/xlh present
larger market oppti includ sucampo scmp mp remind investor amitiza
constip franchis upcom binari catalyst primarili top-lin data
niemann-pick diseas type formal possibl acquisit
mp complet prior earn call
trump budget consist report draconian
bottom line presid trump releas propos budget monday document includ
mani propos outlin previou note link explain detail
recent report council econom advis link presid trump propos budget
outlin number item believ view conjunct report like
cea report budget provid minim detail said budget propos litani pharma-
focus chang includ reform medicaid medicar exclus period
program addit budget propos chang allow physician better util ehr creat
incent provid engag altern payment model apm pledg next
five year combat opioid crisi aggreg believ combin effect
propos massiv unfavor impact suppli chain pbm believ
part rebat flow back plan esrx rebat headwind would off-set
move part part administ pbm distributor believ
would headwind lower part reimburs cost relat opioid howev all-in
estim unfavor ep impact would ep
hh budget propos cut
drug price reform propos medicaid medicar
free use ehr patient data provid incent join apm
remov park brake exclus
combat opioid crisi
link presid budget link
impact distributor
may seek acquir sooner expect
bottom line wall street journal report walgreen mp approach
op potenti take-over talk appear earli stage accord paper
sourc deal may occur assum premium estim deal valu
would walgreen alreadi impli ntm price-to-earnings
stock averag initi assess deal point
ep accret financ debt/equ much higher debt
share esrx may trade
deal line stefano world domin strategi
deal valu could around
deal look accret even stock/debt
bottom line earli talk report wsj even mp op
potenti take-over entir surpris manag perspect reduc
likelihood would acquir op wcg op specul
strateg respons op aet mp merger would also enabl op
continu partnership uninterrupt build-out urgent care medexpress center
stake nation media suggest talk earli stage offer
made
could engag larg inorgan move either acquir
own stake retailer/drug distributor combin esrx mp retail pbm
combin wcg drug retailer/mco combin la cvs/aet
also specul would sell though feb boston manag meet
ceo optum made clear unlik
wba play take retailer/wholesal deal respons on-going vertic consolid
drug suppli chain well threat entri rx/healthcar would point
tradit vertic move pois improv profit drug store giant purchas
power gener brand drug manufactur
abc/ combin like take tabl near-term acquisit
wcg within manag coverag though still possibl move futur
miss larg hix one-tim guidanc encourag
bottom line report accept issu encourag initi guidanc
adjust ep exclud one timer paus share subsidi hix compar
consensu given reset year biggest issu exchang
dwindl membership see report decent normal ep baselin exclud
one-tim per estim exclud importantli ep guidanc
bracket consensu guid revenu consensu in-line
expect resolut consensu given expect hix attrit
path normal margin typic requir shed unprofit busi particularli hix
plagu compani loss six quarter guid tax rate post reform legisl
peer guidanc assum net margin compar target
margin expect run rate basi guid margin
gross health insur fee appear conservat manag host call
tomorrow
accept miss driven larg one timer paus hix cost share subsidi
medicar medicaid improv qoq
guidanc encourag ep bracket consensu revenu in-line
consensu view look reason given unprofit exchang attrit
guidanc appear conservat built margin compar
target expect hix attrit drive meaning margin improv
workforc reduct expand margin much
tax reform adjust guid tax rate peer could higher baselin gross
non deduct health insur provid fee also appear conserv
manag host confer call tomorrow
focu call
recap uncertainti payer contract remain central
bottom line remain outperform broaden genet test busi
set includ reproduct health offer via acquisit start genet
combimatrix deliv revenu access test came
line pre-announce revenu access sampl back januari also reiter
guidanc revenu access test uncertainti lack
visibl loom new test outsid base busi howev guidanc could conserv
secur payer contract drive upsid guid near-term uncertainti
remain confid abl deliv asp combin compani test
volum could potenti upsid number contract operation earlier
continu emphas volum lead metric long-term outlook
numer lever could drive upsid current level
still expect gross margin long run
revenu
initi takeaway fda brief document
bottom line ahead adcom schedul feb fda releas brief
document pacira snda exparel nerv block believ approv exparel
nerv block slam dunk fda rais valid efficaci safeti concern
mainli due variabl inconsist data across four nerv block studi studi
femor nb tka studi brachial plexu nb base discuss medacorp
kol analysi would surpris fda requir pacira work
support expand nerv block indic may either involv re-run entir studi
specif studi protocol run smaller studi better elucid safeti profil
outright approv seem unlik view given concern fda rais brief document
concern rais fda brief document
pk profil suffici elucid applic across broad rang nerv block procedur
durat motor sensori block fulli character
lack bupivacain control-arm studi make assess efficaci difficult
appreci trend reduct opioid consumpt
nerlynx nccn guidelin look consist expect
guidelin date feb includ recommend use nerlynx adjuv treatment
breast cancer view posit like by-and-larg within expect
materi affect estim forecast nerlynx per updat guidelin nerlynx recommend
extend adjuv treatment node-posit stage ii-iii hormone-receptor posit hr
patient consist expect predomin use drug base
clinic data upsid guidelin also includ nerlynx follow perjeta-bas adjuv treatment
aphin indic set drug studi henc current model recal
nccn guidelin repres import nation recogn standard cancer care adher
nccn guidelin import obtain reimburs mani payor includ remain
op rate
per updat nccn guidelin nerlynx recommend node-posit hr diseas
roch perjeta recommend adjuv therapi combin herceptin chemotherapi
hr-neg hr-posit patient node
impact current nerlynx forecast
ep rev disc dcf wacc tg
bottom line yesterday vertex announc us fda approv symdecko tezacaftor/ivacaftor
homozyg residu function cystic fibrosi cf patient press
releas provid initi revenu guidanc approv broadli anticip
consensu came day pdufa date revenu guidanc bracket consensu
estim howev wac price higher orkambi may lead small boost
estim label multipl advantag orkambi lack respiratori event
lack monitor requir blood pressur low lung function patient neg
attribut orkambi limit penetr address popul label
advantag doubl efficaci symdecko could increas homozyg penetr rate
provid robust top-lin growth vertex clinic develop period tripl therapi
start phase trial
revenu guidanc bracket consensu
wac price symdecko premium orkambi
label lack respiratori monitor requir seen orkambi see comparison insid note
ftc suit alleg price collus small dental practic market
bottom line afternoon ftc announc lawsuit henri schein mp
patterson cover benco privat anti-trust price behavior complaint
charg benco conspir violat section ftc act
alleg three compani collud withhold price discount buy group dental
suppli agenc estim firm control dental suppli equip
distribut work togeth depriv independ small practic dentist
benefit particip buy group group purchas organ gpo although
announc new news previous heard market discuss client
around price collus relat entir surpris howev litig
privat parti view sever litig ftc view news
seriou could result long-term margin headwind multipl compress
share after-hour trade like weak tomorrow
execut commun cite evid
trial set octob
 methodolog ep
bottom line maintain mp rais pt report good
guidanc rais tax tailwind expect compani report modest
 beat continu perform exchang off-set flu-driven consolid miss bp
sg also miss estim bp larg due busi expans cost revenu modestli
estim expect ep guid meaning
tax tailwind exchang membership time equiti rais fide transact rais
ep line guidanc compar consensu reflect fide close
commenc april rais ep compar consensu reflect
tax reform tailwind though upsid hipf delay medicaid cross walk
legisl away spend bill repres headwind downgrad
fide hnt plan statu downsid risk includ peak exchang margin
mm expect ep guidanc contempl possibl upsid
rel basi absenc hipf delay tailwind limit upsid well rais pt
contempl price-to-earnings ep
modest beat
revenu modestli beat expect come expect
guidanc revis upward primarili driven tax reform
rais estim
downgrad fide hnt impact bonu payment pose downsid particularli
given propos regul given cross-walk legisl
state ny propos rate clawback design either off-set portion
feder tax reform tailwind case also off-set increas cost hipf
state ny purchas fide profit compani target taxat
addit downsid risk remain peak hix margin
track record medicaid win remain impress
rais pt contempl price-to-earnings ep exhibit
revenu billion adj ep
second program clinic continu valid bold gene
bottom line expect audent announc initi dose
mark compani second gene therapi trx address pediatr patient
posit data could valid compani gene trx platform also remind investor
compani select optim construct pomp diseas along
catecholaminerg polymorph ventricular tachycardia/cpvt could enter clinic
year reiter op bold
migalastat nda accept prioriti review pdufa date aug
bottom line follow nda file link fda accept nda
prioriti review come expect increment posit updat pdufa
goal date aug us revenu could contribut revenu guidanc
announc last month continu see strong growth driver amicu yr
compani continu advanc migalastat galafold fabri diseas
pomp diseas program clinic reiter op
take step forward revers dose remain
bottom line initi revers studi nonalcohol steatohepat nash pt
biopsy-confirm diagnosi cirrhosi follow resolut fda label ocaliva
primari biliari cholangitis/pbc link result revers intend serv
basi seek us intern market author obetichol acid oca
treatment nash compens cirrhosi along regener studi posit
intercept leader race develop nash treatment howev despit differ
patholog nash pbc remain cautiou potenti advers event ae
profil may aris oca dose cirrhot pt reiter mp
sight sore eyes/fund usher new approach ocular
bottom line today prqr issu press releas highlight collabor foundat
fight blind develop prqr candid usher syndrom type
genet condit result progress vision loss term agreement
foundat fight blind provid milestone-bas co-fund paid
prqr preclin clinic advanc opportun repres
second collabor effort report compani month time link
find encourag prqr continu gener momentum around novel rna-bas
therapeut approach current therapi usher syndrom type repres
potenti first-to-market opportun second clinic program rare ocular diseas
link compani expect advanc toward clinic clinic readout
storm polit teacup pharma come trump budget
cea outlin possibl drug price polici draconian
ttr seri part handicap on-going tafamidi trial fac
dcf analysi discount rate tg rate
investor day support on-going studi design market oppti ic/
averag price-to-earnings p/ dcf methodolog
great execut catalyst everi mirvetuximab ph
hcit distribut preview posit coordin vbc cautiou
medic suppli devic individu co preview cardio large-cap diversifi
plan present updat ph ii data tipifarnib hrasm scchn squamou
cell carcinoma head neck multidisciplinari head neck cancer
manag note acceler scchn enrol given
posit data gener date increas physician awar
updat provid patient studi includ updat durat
patient still studi last updat new addit patient studi
believ investor want see continu encourag clinic data well
patient given previous disclos enrol challeng evolv scchn
landscap vs last updat encourag
project probability-adjust tipifarnib scchn sale royalti
phase dose escal interim safeti data expect earli
recal dose escal on-going variou express solid tumor includ
breast cancer patient score greater nsclc patient express
gastric patient posit post herceptin treatment
risk step given antibody-drug conjug fail due toxic concern
particular thrombocytopenia neutropenia gi toxic ocular advers event
pend determin recommend phase ii dose plan initi
cdtx rezafungin iv phase ii data candidemia system candida
phase ii strive data rezafungin iv expect
cdtx share sold significantli earlier topic program
vulvovagin candidiasi discontinu think perceiv read-through
error continu ascrib odd approv underlin robust pharmacokinet
preclin safeti histor echinocandin data
project probability-weight rezafungin sale
celg ph trial revlimid follicular lymphoma
augment trial approach complet top-lin result releas earli
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
top-lin data expect two ph trial
high level convict derm topic acn program stem clinic valid
robust efficaci data ph iib studi highli power ph program pois
deliv definit result pt medacorp kol check support
strong reimburs access uptak prospect given uniqu on-target
mechan action
hyperhidrosi excess sweat pdufa probability-of-
follow recent success complet futil analysi ph
studi asah patient pivot event edg share set in/around
compani conduct interim analysi see binari event
upsid skew risk/reward
compar vs standard care oral nimodipin asah
succeed interim analysi need better oral nimodipin
base case assum odd success
project probability-weight sale
gwph pursu larg market opportun cbdv us
epilepsi patient suffer partial seizur
phase ii success cbdv would add anoth revenu stream leverag
exist infrastructur commerci lead product epidiolex
given small number target rep requir launch epilepsi drug revenu
gener cbdv mostli flow gwph bottom line
furthermor cbdv durabl product rel epidiolex intellectu
properti
mean cbdv success could contribut significantli tail end
valuat gwph stand begin cut epidiolex sale end model
believ littl credit cbdv price stock today success
cbdv repres upsid cautious optimist success
epidiolex part data ph ii/iii infantil spasm
ionis-httrx phase ib data earli albeit under-follow clinic event
think could offer import proof-of-principl antisens strategi huntington diseas
signific unmet medic need hd repres massiv potenti market
opportun novel disease-modifi strategi
upcom ionis-httrx result import potenti roch
also see meaning read-through op whose antisens hd program also
phase ib month behind
project ionis-httrx probability-adjust sale eu
receiv mid-teen royalti
top-lin result expect earli studi test rationally-
design formul commens bacteria resolv dysbiosi colon
manag believ dysbiosi primari cdi less sever effect restor
use lower number bacteri strain compar recurr cdi target
predict probabl success peak risk-adjust us gross
sale estim
believ posit result could enhanc appreci mcrb spore-bas approach
restor gut microbiom provid insight util synthet microbiom
also optimist odds-of-success elagolix uterin fibroid -- consist
consensu view program
partner elagolix mp fund clinical/commerci
develop agre pay royalti sale
mileston
elagolix daili oral gnrh gonadatropin-releas hormon antagonist two
posit ph data set endometriosi uf larger market
forecast gross peak revenu elagolix endometriosi
probabl success po uf po
sourc leerink research compani inform factset price prior day
fda adcom brief doc anesthet analges drug product
fda adcom joint meet anesthet analges drug product drug
safeti risk manag
fda adcom anesthet analges drug product exparel
propos hous appropri committe deadlin fund feder government
fda adcom neurolog devic panel medic devic evalu clinic
data intracrani aneurysm treatment devic
fda adcom gastrointestin drug panel snda xeljanz ulcer
fda adcom joint meet pediatr endocrinolog metabol drug
achondroplasia
pdufa akao plazomycin complic urinari tract infect bloodstream
pdufa revefanacin lama copd
associ access medicin
advanc genom biolog technolog
european crohn coliti organis
advanc technolog treatment diabet
multidisciplinari head neck cancer symposium
american academi dermatolog
bmt tandem meet american societi blood marrow transplant
asbmt center intern blood marrow transplant research cibmtr
societi critic medicin sccm
pittsburgh confer analyt chemistri appli spectroscopi
european congress radiolog ecr
american academi allergi asthma immunolog aaaai /wao
confer retrovirus opportunist infect
intern confer target anti-cancer therapi tat
healthcar inform manag system societi himss
american academi orthopaed surgeon aao
american colleg cardiolog cardiovascular outcom trial
societi inherit metabol disord
societi toxicolog
intern confer alzheim parkinson diseas
hcit distribut preview posit coordin vbc cautiou
medic suppli devic individu co preview cardio large-cap diversifi
 first apprais tax offer small benefit
 state larg cap biotech sfo steadi goe
 preview tax reform guidanc imp catalyst aet
shade grey
 aet creat new front healthcar outperform larsen
manag cvs-aet neutral ep wcg ci
gupt ana
 aet seek creat new low-cost community-bas model
-- flash /aet may closer deal combin would creat
manag -- flash cvs-aet like dec per share mix
 equiti question gupt ana
 volum start show improv respond aggress
 outperform larsen david
manag aet offens defens consum deal
 aet bring comprehens member
-- flash dementia psychosi btd po surpris basket high risk/
aciu kol lunch support target tau ad interim look advanc
aciu recap pipelin w/ new antibodi select cren
aciu -- flash aciu receiv chf roch phase initi anti-
 growth margin management stabil still lack pipelin catalyst
 aducanumab titrat arm bolster evid treatment effect market
 ctad medacorp call aducanumab abeta hypothesi
 lp hic panel controversi focu ahead data
 roll new ttr model updat spinraza pipelin pt market
 synergi specialti purchas aggress medic
hcit distribut outlook increasingli competit suppli chain
shift vbc
hcit distribut amazon estim matter
hcit distribut wholesal licens may start hub spoke
hcit distribut enter brick mortar space pbm deal could
hcit distribut like take modest size step pharmaci
manag entri drug distribut chain
healthcar distribut suppli chain preview price volum trend
manag -- flash marriag aet jilt altar toward
optum wanna-b
-- flash comment stir lab suppli busi back
 state larg cap biotech sfo steadi goe
chang
 first apprais tax offer small benefit
 vertex alexion top pick
controversi focu ahead drug launch
futur major invest theme backdrop clinic risk
-- flash fourier result chang standard cv patient
 fourier lift statin throne plausibl like
 set new slow-growth outlook get excit pt
biopharma -- flash trulic sustain blow sema must show cv benefit
biopharma -- flash bydureon fail show cv benefit posit novo
biopharma -- flash highlight invokana fda warn puls call modest
impact
biopharma leerink confer offer first mani face offswil
 model updat reflect goal achiev w/ pipelin success market
mdco anoth step forward cubist vabomer approv pt
novob dc evolut market make pivot year novo
nv -- flash canto suggest role ilari cv uptak reimburs may
nv -- flash surpris win canto hit primari endpoint await
biopharma ada day takeaway healthcar focu canva
biopharma -- flash highlight invokana fda warn puls call modest
impact
biopharma -- flash jardianc win lose wake invokana
medic suppli devic abt/mdt secur approv diabet devic
medic devic cgm libr impact market uncertain still oversold
medic devic ada wrap-up posit meet devic podd/abt/mdt
medic devic leerink leadership seri outset drive shift dialysi self-
novob dc highlight nvo management roundtabl boston market perform
view market
 guidanc show tax reform payoff hard complain
 upgrad op convict top-lin growth accel stori pt
 ar takeaway -- -excit build ahead sinuva launch outperform
 slow growth outlook price power reced upsid limit pt
biopharma price right payer fail get drug class come
biopharma dupix approv price test new paradigm drug access
 volum price pressur continu reduc estim market
esrx aggress price loss competit market pt market
hcit distribut fda take step improv competit distributor near
 dupix price valu money new
tsro zejula price prompt model valuat updat pt lower
 medacorp call gener posit sinuva reimburs prospect
biotechnology/aan recap sma steal show migrain epilepsi pd psych
 american academi neurolog planner
 futur major invest theme backdrop
 neurosci panel takeaway leerink global
 outlook smid biotech theme rnai/antisens id
gwph qtr recap dinner physician bullish uptak ahead
gwph/aan presentation/kol event -- epidiolex profil continu look favorable/
 build solid foundat xlh data could posit ahead
gwph lower pt better data setup still solid
 own dont part wake
-- flash kol call po risk/benefit support major role orphan
management dinner offer perspect pdp launch/strategi
 management dinner offer perspect pdp launch/strategi potenti
-- flash dementia psychosi btd po surpris basket high risk/
 remov toz model safeti setback all-in pt
re-fil inbrija nda parkinson diseas episod believ issu
 kol dinner offer insight emerg drug psych
 recap sma steal show migrain epilepsi pd psych
 upgrad op overhang remov shot base fda/cn
biopharma name shame california latest strategi rein drug
 price sensit analysi show path share upsid pt
healthcar distribut suppli chain preview price volum trend
hcit distribut brand inflat top show deceler y/i
cautiou
hcit distribut volum price appear cautiou suppli chain
ahead earn
 elast demand consist reduc price drive volum growth
pharmaci benefit manag pbmi confer take-away pbm right
side price debat
biopharma -- flash highlight io combin seri puls call front-lin
biopharma highlight io agonist checkpoint puls call updat
biopharma highlight immuno-oncolog kol discuss
biopharma takeaway io remain major area focu
io clinic trial updat crossroad effici
biopharma catalyst tracker busi year ahead neuro oncolog inflamm
biopharma io combo panel takeaway leerink global healthcar
 deep dive highlight oncolog focu strategi nash market perform
 adcetri deep-div highlight upside/downsid pt
 patent fall hurdl humira cut like pipelin loom
achn recap increment advanc patent complement
acr/ patent issuanc enhanc lt valu could add npv
 patent strategi come focu mitig biosimilar risk outpfrm
 doubl extend patent horizon tecfidera
 took money ranminim valu uplift us patent win
biopharma cafc oral argument justic challeng scope ab patent
 patent issuanc reflect execut strategi pt outperform
 recap data ip progress uk/eu mark new year
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg qed ged late stage failur throw ibd bd
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
 quiet focu remain pot ibs-c partnership catalyst
biopharma viii partnership acquisit biopharma new top list
celg anoth bet car-t probabl probabl sensibl even
 aet bring comprehens member
cori posit updat donepezil pilot studi possibl partnership ye
dplo mid-mkt pbm acquisit complet strateg move market perform
 outperform
 add cscc respons diseas boost /sni
-- flash partner drug advanc phase outperform
 discuss deep dive alks/itci test fda flexibl
alny/ion ttr amyloidosi physician survey
 gwph major takeaway weekend annual
epilepsi meet
 analyst event best idea
outperform
hcit distribut hospit hcit survey highlight shift analyt
healthcar leerink outlook
medic suppli devic survey direct posit
mute hope new indications/improv execut
major highlight medacorp lung cancer survey
focus nsclc
 look diamond rough initi coverag
spec pharma/gener
-- contact leerink repres detail access podcast
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
 pbc survey suggest ocaliva safeti concern manag
 survey payor concern plan upset orphan
 rubraca posit base survey lower est due payer
facil link
hcit distribut demand shift analyt effect use
major medacorp survey lung cancer posit
azn
medic devices-cardiolog tavr survey ew suggest upsid like
reflect share
medic suppli devic survey suggest pickup
 physician survey support nerlynx opp ty breast cancer pt
medic devic survey direct posit mute
tsro ovarian cancer survey affirm parp market upgrad op improv risk/
 leadership seri call highlight foundat improv growth ahead
 leerink leadership seri new product growth acceler stori
medic devic leerink leadership seri bigfoot brink disrupt
medic devic leerink leadership seri outset drive shift dialysi self-
medic devices-cardiolog leerink leadership seri target
 leadership call offer insight multipl hot topic controversi
outlook alpha opportun abound healthcar share
